A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY- MS Baseline Analysis

被引：0
|
作者：
De Stefano, N. [1 ]
Achiron, A. [2 ]
Barkhof, F. [3 ]
Chan, A. [4 ]
Derfuss, T. [5 ]
Hodgkinson, S. [6 ]
Leocani, L. [7 ]
Montalbant, X. [8 ]
Pratt, A. [9 ]
Schmierer, K. [10 ]
Sellebjerg, F. [11 ]
Vermersch, P. [12 ]
Wiendl, H. [13 ]
Keller, B. [14 ]
Roy, S. [15 ]
机构：
[1] Univ Siena, Dept Neurol & Behav Sci, Siena, Italy
[2] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel
[3] Vrije Univ Amsterdam Med Ctr, Dept Radiol, Amsterdam, Netherlands
[4] Univ Bern, Univ Hosp Berne, Bern, Switzerland
[5] Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[6] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, NSW, Australia
[7] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy
[8] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada
[10] Queen Mary Univ London, Blizard Inst Neurosci, Barts & London Sch Med & Dent, London, England
[11] Univ Copenhagen, Rigshosp, Danish MS Ctr, Copenhagen, Denmark
[12] Univ Lille, INSERM, U1172, FHU Imminent,CHU Lille, Lille, France
[13] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany
[14] Merck KGaA, Darmstadt, Germany
[15] Merck, Aubonne, Switzerland
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1262
引用
收藏
页码：685 / 686
页数：2
相关论文
共 50 条
  • [21] Stability of Employment Status Among Patients with Highly Active Relapsing Multiple Sclerosis During the 2-year CLARIFY-MS Study
    Selmaj, K.
    Langdon, D.
    Brochet, B.
    Havrdova, E. K.
    Lechner-Scott, J.
    Montalban, X.
    Patti, F.
    Piehl, F.
    Solari, A.
    Alexandri, N.
    Nolting, A.
    Lehn, A.
    Smyk, A.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 60 - 60
  • [22] Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
    Brochet, Bruno
    Hupperts, Raymond
    Langdon, Dawn
    Solari, Alessandra
    Piehl, Fredrik
    Lechner-Scott, Jeannette
    Montalban, Xavier
    Selmaj, Krzysztof
    Valis, Martin
    Rejdak, Konrad
    Havrdova, Eva K.
    Patti, Francesco
    Alexandri, Nektaria
    Nolting, Axel
    Keller, Birgit
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [23] Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
    Adamec, Ivan
    Jakob, Gregor Brecl
    Rajda, Cecilia
    Drulovic, Jelena
    Radulovic, Ljiljana
    Kes, Vanja Basic
    Lazibat, Ines
    Rimac, Julija
    Cindric, Igor
    Grzincic, Tihana
    Abicic, Ana
    Barun, Barbara
    Gabelic, Tereza
    Gomezelj, Sarah
    Mesaros, Sarlota
    Pekmezovic, Tatjana
    Klivenyi, Peter
    Skoric, Magdalena Krbot
    Habek, Mario
    JOURNAL OF NEUROIMMUNOLOGY, 2023, 382
  • [24] Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
    Brochet, Bruno
    Solari, Alessandra
    Lechner-Scott, Jeannette
    Piehl, Fredrik
    Langdon, Dawn
    Hupperts, Raymond
    Selmaj, Krzysztof
    Patti, Francesco
    Brieva, Luis
    Maida, Eva Maria
    Alexandri, Nektaria
    Smyk, Andrzej
    Nolting, Axel
    Keller, Birgit
    Montalban, Xavier
    Kubala Havrdova, Eva
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (14) : 1808 - 1818
  • [25] The effect of natalizumab on brain atrophy in patients with relapsing multiple sclerosis: 2-year results from the AFFIRM study
    Fisher, E
    O'Connor, R
    Havrdova, E
    Hutchinson, M
    Kappos, L
    Miller, D
    Phillips, JT
    Polman, C
    Lublin, R
    Giovannoni, G
    Wajgt, A
    Rudick, R
    Lynn, F
    Toal, M
    Panzara, M
    Sandrock, A
    JOURNAL OF NEUROLOGY, 2005, 252 : 149 - 149
  • [26] EFFICACY OF CLADRIBINE TABLETS IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS: ANALYSIS OF POOLED DOUBLE-BLIND DATA FROM THE CLARITY AND ONWARD STUDIES
    Giovannoni, Gavin
    Montalban, Xavier
    Rammohan, Kottil
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    King, John
    Damian, Doris
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E27 - E28
  • [27] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Adeniji, Abidemi K.
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
  • [28] Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS (vol 9, e1187, 2022)
    de Stefano, N.
    Barkhof, F.
    Montalban, X.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (06):
  • [29] Safety and tolerability of cladribine tablets added to IFN-beta therapy in patients with active relapsing multiple sclerosis: final results from the ONWARD study (amended protocol)
    Montalban, X.
    Cohen, B.
    Leist, T.
    Moses, H.
    Hicking, C.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 409 - 410
  • [30] Efficacy of cladribine tablets 3.5 mg/kg in patients with highly active relapsing multiple sclerosis (RMS): Pooled analysis of the double-blind cohort from CLARITY and ONWARD
    Giovannoni, G.
    Montalban, X.
    Damian, D.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 332 - 332
12345